Kalyra Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused on creating best-in-class medicines that address unmet needs in the area of pain management, anti-infectives and fibrosis. We aim to improve patient outcomes by developing modified molecules that retain the efficacy of commonly used medications while reducing or eliminating unwanted side effects and safety concerns. Our proprietary chemistry based platform has proven successful in generating an effective pain medication while eliminating an existing safety concern. In 2015 Zeno Pharmaceuticals made a $15 million equity investment.
Kalyra Pharmaceuticals – Spun-off Zentalis Pharmaceuticals which IPO’d in 2020 (8x multiple)Arash Sani2021-09-12T08:23:19-08:00